Long-term effectiveness and drug survival of apremilast in treating psoriasis: a real-world experience

J Distel, S Cazzaniga, SM Seyed Jafari, V Emelianov… - Dermatology, 2022 - karger.com
Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Apremilast in psoriasis–a prospective real‐world study

I Vujic, R Herman, M Sanlorenzo… - Journal of the …, 2018 - Wiley Online Library
Background Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real …

Efficacy and safety of apremilast monotherapy for moderate to severe psoriasis: retrospective study

A Ighani, JR Georgakopoulos, LL Zhou… - Journal of …, 2018 - journals.sagepub.com
Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Real‐world, single‐centre experience of apremilast for the treatment of moderate to severe psoriasis

TH Wong, S Sinclair, B Smith, C Fraser… - Clinical and …, 2017 - academic.oup.com
The introduction of several new therapeutic agents, predominantly biologic therapies, has
transformed the management of moderate and severe psoriasis in recent years. A novel oral …

Real-world experience with apremilast in treating psoriasis

JN Mayba, MJ Gooderham - Journal of cutaneous medicine …, 2017 - journals.sagepub.com
Background: Clinical trial data have shown apremilast, an oral phosphodiesterase-4
inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world …

Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

MLF Knuckles, E Levi, J Soung - Journal of Dermatological …, 2019 - Taylor & Francis
Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long‐term experience

C Galache‐Osuna, S Reyes‐García… - Dermatologic …, 2022 - Wiley Online Library
There is limited evidence about the real‐world survival of apremilast in patients with
psoriasis, especially over the long term. To evaluate the long‐term survival of apremilast and …

[HTML][HTML] Apremilast in psoriasis patients with serious comorbidities: a case series and systematic review of literature

A Tsentemeidou, E Sotiriou, N Sideris… - Dermatology Practical …, 2022 - ncbi.nlm.nih.gov
Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

[HTML][HTML] The use of apremilast in psoriasis: a Delphi study

JM Carrascosa, I Belinchón, R Rivera, M Ara… - Actas Dermo …, 2020 - Elsevier
Background Experience in the use of apremilast in clinical practice complements the
information available from pivotal clinical trials. Materials and methods Following a review of …

Efficacy and safety of apremilast in the treatment of patients with mild-to-moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open-label, single-arm …

Y Okubo, H Takahashi, R Hino, K Endo… - Dermatology and …, 2022 - Springer
Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …